MeiraGTx Holdings plc Research and Development Expense
MeiraGTx Holdings plc (MGTX) reported Research and Development Expense of $57.83 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- MeiraGTx Holdings plc research and development expense for the quarter ending 2026-06-30 was $57.83M, a 72.66% increase year-over-year.
- MeiraGTx Holdings plc research and development expense for the quarter ending 2026-03-31 was $31.98M, a 2.43% decline year-over-year.
- MeiraGTx Holdings plc research and development expense for the quarter ending 2025-12-31 was $30.81M, a 28.46% increase year-over-year.
- MeiraGTx Holdings plc research and development expense for the quarter ending 2025-09-30 was $32.53M, a 23.96% increase year-over-year.
- MeiraGTx Holdings plc research and development expense for fiscal 2025 was $129.62M, a 8.48% increase from fiscal 2024.
- MeiraGTx Holdings plc research and development expense for fiscal 2024 was $119.48M, a 15.13% increase from fiscal 2023.
- MeiraGTx Holdings plc research and development expense for fiscal 2023 was $103.78M, a 21.07% increase from fiscal 2022.
- MeiraGTx Holdings plc research and development expense for fiscal 2022 was $85.72M, a 28.53% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $57.83M 10-Q · filed 2026-08-13 | $89.82M 10-Q · filed 2026-08-13 | $120.63M derived: sum of 3 quarters · filed 2026-08-13 | $153.16M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $31.98M 10-Q · filed 2026-05-14 | $62.80M derived: sum of 2 quarters · filed 2026-05-14 | $95.33M derived: sum of 3 quarters · filed 2026-05-14 | $128.82M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $30.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $63.34M derived: sum of 2 quarters · filed 2026-03-30 | $96.84M derived: sum of 3 quarters · filed 2026-08-13 | $129.62M 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $32.53M 10-Q · filed 2025-11-13 | $66.03M derived: sum of 2 quarters · filed 2026-08-13 | $98.81M 10-Q · filed 2025-11-13 | $122.79M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $33.49M 10-Q · filed 2026-08-13 | $66.28M 10-Q · filed 2026-08-13 | $90.26M derived: sum of 3 quarters · filed 2026-08-13 | $116.50M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $32.78M 10-Q · filed 2026-05-14 | $56.77M derived: sum of 2 quarters · filed 2026-05-14 | $83.01M derived: sum of 3 quarters · filed 2026-05-14 | $117.94M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | $23.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $50.23M derived: sum of 2 quarters · filed 2026-03-30 | $85.16M derived: sum of 3 quarters · filed 2026-03-30 | $119.48M 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $26.24M 10-Q · filed 2025-11-13 | $61.18M derived: sum of 2 quarters · filed 2025-11-13 | $95.50M 10-Q · filed 2025-11-13 | $129.17M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $34.93M 10-Q · filed 2025-08-14 | $69.26M 10-Q · filed 2025-08-14 | $102.93M derived: sum of 3 quarters · filed 2025-08-14 | $130.78M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $34.32M 10-Q · filed 2025-05-13 | $67.99M derived: sum of 2 quarters · filed 2025-05-13 | $95.85M derived: sum of 3 quarters · filed 2025-05-13 | $115.78M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $33.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $61.53M derived: sum of 2 quarters · filed 2025-03-13 | $81.46M derived: sum of 3 quarters · filed 2025-03-13 | $103.78M 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | $27.86M 10-Q · filed 2024-11-13 | $47.79M derived: sum of 2 quarters · filed 2024-11-13 | $70.11M 10-Q · filed 2024-11-13 | $91.88M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $19.94M 10-Q · filed 2024-08-12 | $42.26M 10-Q · filed 2024-08-12 | $64.02M derived: sum of 3 quarters · filed 2024-08-12 | $80.89M derived: sum of 4 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | $22.32M 10-Q · filed 2024-05-09 | $44.09M derived: sum of 2 quarters · filed 2024-05-09 | $60.95M derived: sum of 3 quarters · filed 2024-05-09 | $84.95M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $21.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $38.63M derived: sum of 2 quarters · filed 2024-03-15 | $62.63M derived: sum of 3 quarters · filed 2024-03-15 | $85.72M 10-K · filed 2024-03-15 | ||||
| 2022-09-30 | $16.86M 10-Q · filed 2023-11-14 | $40.86M derived: sum of 2 quarters · filed 2023-11-14 | $63.96M 10-Q · filed 2023-11-14 | $77.14M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $24.00M 10-Q · filed 2023-08-10 | $47.10M 10-Q · filed 2023-08-10 | $60.28M derived: sum of 3 quarters · filed 2023-08-10 | $81.89M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $23.10M 10-Q · filed 2023-05-11 | $36.28M derived: sum of 2 quarters · filed 2023-05-11 | $57.89M derived: sum of 3 quarters · filed 2023-05-11 | $73.08M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $13.18M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $34.80M derived: sum of 2 quarters · filed 2023-03-14 | $49.98M derived: sum of 3 quarters · filed 2023-03-14 | $66.69M 10-K · filed 2023-03-14 | $67.13M 10-K · filed 2022-03-10 | |||
| 2021-09-30 | $21.61M 10-Q · filed 2022-11-10 | $21.61M 10-Q · filed 2021-11-10 | $36.80M derived: sum of 2 quarters · filed 2022-11-10 | $53.51M 10-Q · filed 2022-11-10 | $58.51M derived: sum of 4 quarters · filed 2022-11-10 | |||
| 2021-06-30 | $15.19M 10-Q · filed 2022-08-11 | $31.90M 10-Q · filed 2022-08-11 | $36.90M derived: sum of 3 quarters · filed 2022-08-11 | $41.52M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $16.71M 10-Q · filed 2022-05-12 | $21.71M derived: sum of 2 quarters · filed 2022-05-12 | $26.33M derived: sum of 3 quarters · filed 2022-05-12 | $42.54M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $9.63M derived: sum of 2 quarters · filed 2022-03-10 | $25.83M derived: sum of 3 quarters · filed 2022-03-10 | $33.91M 10-K · filed 2022-03-10 | $33.91M 10-K · filed 2021-03-11 | |||
| 2020-09-30 | $4.63M 10-Q · filed 2021-11-10 | $4.63M 10-Q · filed 2020-11-05 | $20.83M derived: sum of 2 quarters · filed 2021-11-10 | $28.91M 10-Q · filed 2021-11-10 | $28.91M 10-Q · filed 2020-11-05 | $26.42M derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $16.20M 10-Q · filed 2021-08-11 | $16.20M 10-Q · filed 2020-08-06 | $24.29M 10-Q · filed 2021-08-11 | $24.29M 10-Q · filed 2020-08-06 | $21.80M derived: sum of 3 quarters · filed 2021-08-11 | $26.41M derived: sum of 4 quarters · filed 2021-08-11 | ||
| 2020-03-31 | $8.08M 10-Q · filed 2021-05-11 | $8.08M 10-Q · filed 2020-05-07 | $5.60M derived: sum of 2 quarters · filed 2021-05-11 | $10.21M derived: sum of 3 quarters · filed 2021-05-11 | $19.98M derived: sum of 4 quarters · filed 2021-05-11 | |||
| 2019-12-31 | -$2.49M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $2.13M derived: sum of 2 quarters · filed 2021-03-11 | $11.90M derived: sum of 3 quarters · filed 2021-03-11 | $24.88M 10-K · filed 2021-03-11 | ||||
| 2019-09-30 | $4.61M 10-Q · filed 2020-11-05 | $14.39M derived: sum of 2 quarters · filed 2020-11-05 | $27.36M 10-Q · filed 2020-11-05 | $38.16M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | $9.77M 10-Q · filed 2020-08-06 | $22.75M 10-Q · filed 2020-08-06 | $33.54M derived: sum of 3 quarters · filed 2020-08-06 | $41.65M derived: sum of 4 quarters · filed 2020-08-06 | ||||
| 2019-03-31 | $12.98M 10-Q · filed 2020-05-07 | $23.77M derived: sum of 2 quarters · filed 2020-05-07 | $31.88M derived: sum of 3 quarters · filed 2020-05-07 | $39.67M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | $10.79M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $18.90M derived: sum of 2 quarters · filed 2020-03-11 | $26.69M derived: sum of 3 quarters · filed 2020-03-11 | $33.62M 10-K · filed 2020-03-11 | ||||
| 2018-09-30 | $8.11M 10-Q · filed 2019-11-07 | $15.90M derived: sum of 2 quarters · filed 2019-11-07 | $22.83M 10-Q · filed 2019-11-07 | $28.61M derived: sum of 4 quarters · filed 2019-11-07 | ||||
| 2018-06-30 | $7.79M 10-Q · filed 2019-08-07 | $14.72M 10-Q · filed 2019-08-07 | $20.50M derived: sum of 3 quarters · filed 2019-08-07 | $26.89M derived: sum of 4 quarters · filed 2019-08-07 | ||||
| 2018-03-31 | $6.93M 10-Q · filed 2019-05-14 | $12.71M derived: sum of 2 quarters · filed 2019-05-14 | $19.10M derived: sum of 3 quarters · filed 2019-05-14 | $24.46M derived: sum of 4 quarters · filed 2019-05-14 | ||||
| 2017-12-31 | $5.78M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $12.17M derived: sum of 2 quarters · filed 2019-03-26 | $17.54M derived: sum of 3 quarters · filed 2019-03-26 | $22.36M 10-K · filed 2019-03-26 | ||||
| 2017-09-30 | $6.39M 10-Q · filed 2018-11-08 | $11.75M derived: sum of 2 quarters · filed 2018-11-08 | $16.58M 10-Q · filed 2018-11-08 | |||||
| 2017-06-30 | $5.36M 10-Q · filed 2018-08-08 | $10.19M 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |